Results From the First Multicenter, Open-label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE)
- Resource Type
- Article
- Source
- In
Clinical Breast Cancer June 2019 19(3):216-224 - Subject
- Language
- ISSN
- 1526-8209